Current HIV therapeutics: Mechanistic and chemical determinants of toxicity

Current Opinion in Drug Discovery and Development

Volumn 12, Issue 1, 2009, Pages 53-60

  Chiao, S ^a   Romero, D L ^b   Johnson, D E ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Emiliem Inc   (United States)

Author keywords

AIDS therapeutics; HIV AIDS; Mitochondrial toxicity; Pharmacogenetics

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMPRENAVIR PHOSPHATE; ATAZANAVIR; DARUNAVIR; DELAVIRDINE; DIDANOSINE; DNA DIRECTED DNA POLYMERASE GAMMA; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENFUVIRTIDE; ETRAVIRINE; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; MARAVIROC; NELFINAVIR; NEVIRAPINE; RALTEGRAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; LACTIC ACIDOSIS; LIPODYSTROPHY; MITOCHONDRIAL DNA DEPLETION; MITOCHONDRIAL TOXICITY; PRACTICE GUIDELINE; REVIEW;

ANIMALS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DNA, MITOCHONDRIAL; GENETIC PREDISPOSITION TO DISEASE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MITOCHONDRIA; REVERSE TRANSCRIPTASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 58449127521     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. Osborn JE: The past, present and future of AIDS. J Am Med Assoc (2008) 300(5):581-583.
2. Shearer W: HIV/AIDS: Waiting for a cure. J Allergy Clin Immunol (2008) 122(1):34-35.
3. Santiago ML, Montano M, Benitez R, Messer RJ, Yonemoto W, Chesebro B, Hasenkrug KJ, Greene WC: Apobec3 encodes Rfv3, a gene influencing neutralizing antibody control of retrovirus infection. Science (2008) 321(5894):1343-1346. • Describes the first indication of a promising approach for future vaccine development.
4. Kohler J, Hosseini S, Lewis W: Mitochondrial DNA impairment in nucleoside reverse transcriptase inhibitor-associated cardiomyopathy. Chem Res Toxicol (2008) 21(5):990-996. •• Authoritative report on the comorbidities that are associated with HIV/AIDS and therapy.
5. Hall HI, Song R, Rhodes P, Prejean J, An Q, Lee LM, Karon J, Brookmeyer R, Kaplan EH, McKenna MT, Janssen RS: Estimation of HIV incidence in the United States. J Am Med Assoc (2008) 300(5):520-529. • Provides definitive statistics on the incidence and growth of HIV in the US.
6. Shen L, Siliciano RF: Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection. J Allergy Clin Immunol (2008) 122(1):22-28.
7. Phillips EJ, Mallal SA: Pharmacogenetics and the potential for the individualization of antiretroviral therapy. Curr Opin Infect Dis (2008) 21(1):16-24. •• Excellent review of how pharmacogenetics can drive a personalized approach to therapy.
8. Hammer SM, Eron JJ Jr, Reiss P, Schooley RT, Thompson MA, Walmsley S, Cahn P, Fischl MA, Gatell JM, Hirsch MS, Jacobsen DM et al: Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society - USA panel. J Am Med Assoc (2008) 300(5):555-570. •• Provides up-to-date recommendations for the antiretroviral treatment of AIDS and reviews of why certain therapy combinations have been selected.
9. Brinkman K: Editorial response: Hyperlactatemia and hepatic steatosis as features of mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors. Clin Infect Dis (2000) 31(1):167- 169.
10. Desai N, Mullen P, Mathur M: Lipodystrophy in pediatric HIV. Indian J Pediatr (2008) 75(4):351-354.
11. Dieterich DT, Robinson PA, Love J, Stern JO: Drug-induced liver injury associated with the use of non-nucleoside reverse-transcriptase inhibitors. Clin Infect Dis (2004) 38(Suppl 2):S80-S89.
12. Foster C, Lyall H: HIV and mitochondrial toxicity in children. J Antimicrob Chemother (2008) 61(1):8-12.
13. González-Requena D, Núñez M, Jiménez-Nacher I, González-Lahoz J, Soriano V: Liver toxicity of lopinavir-containing regimens in HIV-infected patients with or without hepatitis C coinfection. AIDS Res Human Retroviruses (2004) 20(7):698-700.
14. Greene W: The brightening future of HIV therapeutics. Nature Immunol (2005) 5(9):867-871.
15. Kino T, De Martino MU, Charmandari E, Mirani M, Chrousos GP: Tissue glucocorticoid resistance/hypersensitivity syndromes. J Steroid Biochem Mol Biol (2003) 85(2-5):457-467.
16. Lewis W, Day BJ, Kohler JJ, Hosseini SH, Chan SS, Green EC, Haase CP, Keebaugh ES, Long R, Ludaway T, Russ R et al: Decreased mtDNA, oxidative stress, cardiomyopathy, and death from transgenic cardiac targeted human mutant polymerase γ. Lab Invest (2007) 87(4):326-335.
17. Murata H, Hruz P, Mueckler M: The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem (2000) 275(27):20251-20254.
18. Omolayo O, Sealy P: HIV lipodystrophy syndrome. Hospital Physician (2008) 44(5):7-14.
19. Opii WO, Sultana R, Abdul HM, Ansari MA, Nath A, Butterfield DA: Oxidative stress and toxicity induced by the nucleoside reverse transcriptase inhibitor (NRTI)-2′,3′-dideoxycytidine (ddC): Relevance to HIV-dementia. Exp Neurol (2007) 204(1):29-38.
20. Phenix BN, Lum JJ, Nie Z, Sanchez-Dardon J, Badley AD: Antiapoptotic mechanism of HIV protease inhibitors: Preventing mitochondrial transmembrane potential loss. Blood (2001) 98(4):1078-1085.
21. Wierzbicki AS, Purdon SD, Hardman TC, Kulasegaram R, Peters BS: Clinical aspects of the management of HIV lipodystrophy. Br J Diabetes Vasc Dis (2008) 8(3):113-119.
22. Taylor BS, Sobieszczyk ME, McCutchan FE, Hammer SM: The challenge of HIV-1 subtype diversity. N Engl J Med (2008) 358(15):1590- 1602.
23. He W, Neil S, Kulkarni H, Wright E, Agan BK, Marconi VC, Dolan MJ, Weiss RA, Ahuja SK: Duffy antigen receptor for chemokines mediates trans-infection of HIV-1 from red blood cells to target cells and affects HIV-AIDS susceptibility. Cell Host Microbe (2008) 4(1):52-62. •• Provides clear evidence of a link between the susceptibility in individuals to AIDS and malaria.
24. Gonzalez E, Kulkarni H, Bolivar H, Mangano A, Sanchez R, Catano G, Nibbs RJ, Freedman BI, Quinones MP, Bamshad MJ, Murthy KK et al: The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science (2005) 307(5714):1434-1440.
25. Lucas A, Nolan D, Mallal S: HLA-B*5701 screening for susceptibility to abacavir hypersensitivity. J Antimicrob Chemother (2007) 59(4):591-593. • Important paper that demonstrates, along with reference [26], the methods for prospective screening for adverse drug reactions.
26. Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, Jägel-Guedes E, Rugina S, Kozyrev O, Cid JF, Hay P et al: HLA-B*5701 screening for hypersensitivity to Abacavir. N Engl J Med (2008) 358(6):568-579. • Important paper that demonstrates, along with reference [25], the methods for prospective screening for adverse drug reactions.
27. Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, Jacobsen DM, Thompson MA, Carpenter CC, Fischl MA, Gazzard BG, Gatell JM et al: Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society - USA panel. J Am Med Assoc (2006) 296(7):827- 843.
28. Warnke D, Barreto J, Temesgen Z: Antiretroviral drugs. J Clin Pharmacol (2007) 47(12):1570-1579.
29. Beauséjour Y, Tremblay MJ: Susceptibility of HIV type 1 to the fusion inhibitor T-20 is reduced on insertion of host intercellular adhesion molecule 1 in the virus membrane. J Infect Dis (2004) 190(5):894-902.
30. Bewley C, Louis J, Ghirlando R, Clore G: Design of a novel peptide inhibitor of HIV fusion that disrupts the internal trimeric coiled-coil of gp41. J Biol Chem (2002) 277(16):14238-14245.
31. Buckheit RW Jr, Watson K, Fliakas-Boltz V, Russell J, Loftus TL, Osterling MC, Turpin JA, Pallansch LA, White EL, Lee JW, Lee SH et al: SJ-3366, a unique and highly potent nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1) that also inhibits HIV-2. Antimicrob Agents Chemother (2001) 45(2):393-400.
32. Dieleman JP, Jambroes M, Gyssens IC, Sturkenboom MC, Stricker BH, Mulder WM, de Wolf F, Weverling GJ, Lange JM, Reiss P, Brinkman K: Determinants of recurrent toxicity-driven switches of highly active antiretroviral therapy. The ATHENA cohort. AIDS (2002) 16(5):737-745.
33. De Clercq E: Non-nucleoside reverse transcriptase inhibitors (NNRTIs): Past, present and future. Chem Biodivers (2004) 1(1):44-64.
34. Cooley LA, Lewin SR: HIV-1 cell entry and advances in viral entry inhibitor therapy. J Clin Virol (2003) 26(2):121-132.
35. Cooper DA, Lange JM: Peptide inhibitors of virus-cell fusion: Enfuvirtide as a case study in clinical discovery and development. Lancet Infect Dis (2004) 4(7):426-436.
36. Depollier J, Hourdou ML, Aldrian-Herrada G, Rothwell P, Restle T, Divita G: Insight into the mechanism of a peptide inhibitor of HIV reverse transcriptase dimerization. Biochemistry (2005) 44(6):1909- 1918.
37. Rodríguez-Nóvoa S, Barreiro P, Jiménez-Nácher I, Soriano V: Overview of the pharmacogenetics of HIV therapy. Pharmacogenomics J (2006) 6(4):234-245.
38. Eron JJ, Gulick RM, Bartlett JA, Merigan T, Arduino R, Kilby JM, Yangco B, Diers A, Drobnes C, DeMasi R, Greenberg M et al: Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV. J Infect Dis (2004) 189(6):1075-1083.
39. Fung HB, Guo Y: Enfuvirtide: A fusion inhibitor for the treatment of HIV infection. Clin Ther (2004) 26(3):352-378.
40. Greenberg ML, Cammack N: Resistance to enfuvirtide, the first HIV fusion inhibitor. J Antimicrob Chemother (2004) 54(2):333-340.
41. Hernández B, Moreno S, Pérez-Elías MJ, Casado JL, Dronda F, Moreno A, Antela A: Severity of the toxicity associated with combinations that include didanosine plus stavudine in HIV-infected experienced patients. J Acquir Immune Defic Syndr (2006) 43(5):556-559.
42. Jacobson JM, Israel RJ, Lowy I, Ostrow NA, Vassilatos LS, Barish M, Tran DN, Sullivan BM, Ketas TJ, O'Neill TJ, Nagashima KA et al: Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542. Antimicrob Agents Chemother (2004) 48(2):423-429.
43. Lalezari JP, Eron JJ, Carlson M, Cohen C, DeJesus E, Arduino RC, Gallant JE, Volberding P, Murphy RL, Valentine F, Nelson EL et al: A phase II clinical study of the long-term safety and antiretroviral activity of enfuvirtide-based antiretroviral therapy. AIDS (2003) 17(5):691-698.
44. Liu S, Lu H, Niu J, Xu Y, Wu S, Jiang S: Different from the HIV fusion inhibitor C34, the anti-HIV drug fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120. J Biol Chem (2005) 280(12):11259-11273.
45. Mehta U, Maartens G: Is it safe to switch between efavirenz and nevirapine in the event of toxicity? Lancet Infect Dis (2007) 7(11):733-738.
46. Miller M, Hazuda D: HIV resistance to the fusion inhibitor enfuvirtide: Mechanisms and clinical implications. Drug Resist Updat (2004) 7(2):89-95.
47. Moyle G: Stopping HIV fusion with enfuvirtide: The first step to extracellular HAART. J Antimicrob Chemother (2003) 51(2):213-217.
48. Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B et al: Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. Cell (2007) 129(2):263-275.
49. Pollard R, Robinson P, Dransfield K: Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. Clin Ther (1998) 20(6):1071-1092.
50. Portsmouth S, Stebbing J, Gill J, Mandalia S, Bower M, Nelson M, Bower M, Gazzard B: A comparison of regimens based on non-nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi's sarcoma. AIDS (2003) 17(11):F17-F22.
51. Poveda E, Briz V, Soriano V: Enfuvirtide, the first fusion inhibitor to treat HIV infection. AIDS Rev (2005) 7(3):139-147.
52. Romero DL, Busso M, Tan CK, Reusser F, Palmer JR, Poppe SM, Aristoff PA, Downey KM, So AG, Resnick L, Tarpley W: Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication. Proc Natl Acad Sci USA (1991) 88(19):8806-8810.
53. Wang Z, Vince R: Design and synthesis of dual inhibitors of HIV reverse transcriptase and integrase: Introducing a diketoacid functionality into delavirdine. Bioorg Med Chem (2008) 16(7):3587-3595.
54. Flexner C: HIV-protease inhibitors. N Engl J Med (1998) 338(18):1281-1292.
55. Schinazi R, Hernandez-Santiago B, Hurwitz S: Pharmacology of current and promising nucleosides for the treatment of human immunodeficiency viruses. Antiviral Res (2006) 71(2-3):322-334.
56. Kohler JJ, Lewis W: A brief overview of mechanisms of mitochondrial toxicity from NRTIs. Environ Mol Mutagen (2007) 48(3-4):166- 172. • Provides an important discussion on mechanisms related to mitochondrial toxicity.
57. Pinti M, Salomoni P, Cossarizza A: Anti-HIV drugs and the mitochondria. Biochim Biophys Acta (2006) 1757(5-6):700-707.
58. Brinkman K, ter Hofstede HJ, Burger DM, Smeitink JA, Koopmans PP: Adverse effects of reverse transcriptase inhibitors: Mitochondrial toxicity as common pathway. AIDS (1998) 12(14):1735-1744.
59. Lewis W, Kohler J, Hosseini S, Haase C, Copeland W, Bienstock R, Ludaway T, McNaught J, Russ R, Stuart T, Santoianni R: Antiretroviral nucleosides, deoxynucleotide carrier and mitochondrial DNA: Evidence supporting the DNA pol-γ hypothesis. AIDS (2006) 20(5):675-684.
60. Anderson P, Lamba J, Aquilante C, Schuetz E, Fletcher C: Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: A pilot study. J Acquir Immune Defic Syndr (2006) 42(4):441-449.
61. Lee H, Hanes J, Johnson K: Toxicity of nucleoside analogues used to treat AIDS and the selectivity of the mitochondrial DNA polymerase. Biochemistry (2003) 42(50):14711-14719.
62. Samuels DC: Computational models of antiviral toxicity. Curr Opin Drug Discov Devel (2007) 10(1):43-48.
63. Bienstock R, Copeland W: Molecular insights into NRTI inhibition and mitochondrial toxicity revealed from a structural model of the human mitochondrial DNA polymerase. Mitochondrion (2004) 4(2-3):203-213.
64. Lim SE, Ponamarev MV, Longley MJ, Copeland WC: Structural determinants in human DNA polymerase γ account for mitochondrial toxicity from nucleoside analogs. J Mol Biol (2003) 329(1):45-57.
65. Feng JY, Johnson AA, Johnson KA, Anderson KS: Insights into the molecular mechanism of mitochondrial toxicity by AIDS drugs. J Biol Chem (2001) 276(26):23832-23837.
66. Dykens J, Will, Y: The significance of mitochondrial toxicity testing in drug development. Drug Disc Today (2007) 12(17/18):777-785.
67. Nadanaciva S, Bernal A, Aggeler R, Capaldi R, Will Y: Target identification of drug induced mitochondrial toxicity using immunocapture based OXPHOS activity assays. Toxicol In Vitro (2007) 21(5):902-911.
68. Huang H, Chopra R, Verdine G, Harrison S: Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: Implications for drug resistance. Science (1998) 282(5394):1669-1675.
69. Shafer RW, Kantor R, Gonzales MJ: The genetic basis of HIV-1 resistance to reverse transcriptase and protease inhibitors. AIDS Rev (2000) 2(4):211-228.